Emmanuel Raffoux
Overview
Explore the profile of Emmanuel Raffoux including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
184
Citations
5213
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tran C, De Kerviler E, Bergeron A, Raffoux E, Xhaard A, de Bazelaire C, et al.
PLoS One
. 2025 Jan;
20(1):e0316459.
PMID: 39746058
Objective: Febrile neutropenia (FN) is a serious clinical event, associated with significant morbidity and mortality. Imaging has a central role in the identification of the fever cause. The study objectives...
2.
Pacchiardi K, de Marcellus V, Huynh T, Fodil S, Kim R, Bello R, et al.
Cytometry B Clin Cytom
. 2024 Nov;
108(1):86-94.
PMID: 39600238
BH3 profiling can assess global mitochondrial priming and dependence of leukemic cells on specific BH3 anti-apoptotic proteins such as BCL-2. In acute myeloid leukemia (AML), proof-of-concept prognostic studies have been...
3.
Cluzeau T, Guolo F, Chiche E, Minetto P, Rahme R, Bertoli S, et al.
Blood Adv
. 2024 Oct;
9(4):752-758.
PMID: 39454204
CPX-351 has been approved for patients with therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (MRC-AML). No extensive data are available on measurable residual disease (MRD) and long-term...
4.
Chevallier P, Leguay T, Delord M, Salek C, Kim R, Huguet F, et al.
J Clin Oncol
. 2024 Oct;
42(36):4327-4341.
PMID: 39418626
Purpose: The use of inotuzumab ozogamicin (InO), a conjugated anti-CD22 monoclonal antibody, is becoming a promising frontline treatment for older patients with ALL. Patients And Methods: EWALL-INO is an open-label...
5.
Puisset F, Raffoux E, Ades L, Huynh T, Itzykson R, Bouscary D, et al.
Haematologica
. 2024 Oct;
PMID: 39415682
Not available.
6.
Houot R, Calmettes C, Park S, Pascal L, Peffault de Latour R, Pigneux A, et al.
Bull Cancer
. 2024 Sep;
111(10):980-986.
PMID: 39266427
In response to the French hospital system crisis and the challenges faced by the heads of departments, we have undertaken an initiative to create a community of heads of haematology...
7.
Denis B, Resche-Rigon M, Raffoux E, Ronchetti A, Dudoignon E, Verillaud B, et al.
Open Forum Infect Dis
. 2024 Aug;
11(8):ofae426.
PMID: 39183813
Background: The aim of this study was to assess the epidemiology, clinical manifestations, and outcome of mucormycosis over 15 years in a single center in France. Methods: We conducted a...
8.
Kim R, Chalandon Y, Rousselot P, Cayuela J, Huguet F, Balsat M, et al.
J Clin Oncol
. 2024 Jul;
42(26):3140-3150.
PMID: 39028928
Purpose: quantification is widely regarded as the standard for monitoring measurable residual disease (MRD) in Philadelphia chromosome-positive (Ph+) ALL. However, recent evidence of multilineage involvement questions the significance of MRD....
9.
Walczak P, Fodil S, Vignal N, Cabannes-Hamy A, Boissel N, Raffoux E, et al.
Blood
. 2024 Jun;
144(10):1127-1130.
PMID: 38917352
Tyrosine kinase inhibitors efficacy in central nervous system (CNS) disease remains uncertain. Ponatinib was studied for CNS distribution in 16 patients with Philadelphia-positive acute lymphoblastic leukemia. Cerebrospinal fluid concentrations fell...
10.
Kelly L, Rutter J, Lin K, Ling F, Duchmann M, Latour E, et al.
Nat Cancer
. 2024 May;
5(7):1082-1101.
PMID: 38816660
Dose-limiting toxicity poses a major limitation to the clinical utility of targeted cancer therapies, often arising from target engagement in nonmalignant tissues. This obstacle can be minimized by targeting cancer...